

The Metabolic Syndrome and Concentrations of C-Reactive Protein Among U.S. Youth

EARL S. FORD, MD, MPH
UMED A. AJANI, MBBS, MPH
ALI H. MOKDAD, PHD

OBJECTIVE — Adults with the metabolic syndrome show biochemical evidence of low-grade inflammation. We sought to examine whether this is true among U.S. youth with the metabolic syndrome.

RESEARCH DESIGN AND METHODS — We used data from 1,366 participants aged 12–17 years from the National Health and Nutrition Examination Survey 1999–2000. A modification of the definition of the metabolic syndrome proposed by the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults was used. C-reactive protein (CRP) was measured by latex-enhanced nephelometry.

RESULTS — Mean and median concentrations of CRP were higher among participants who had the metabolic syndrome (mean 3.8 mg/l, geometric mean 1.8 mg/l) than among those who did not (mean 1.4 mg/l, geometric mean 0.4 mg/l). The percentage of participants with a concentration of CRP >3.0 mg/l was 38.4% among those with the metabolic syndrome and 10.3% among those without the syndrome ($P = 0.007$). Of the five components of the syndrome, only abdominal obesity was significantly and independently associated with log-transformed concentrations of CRP in multiple linear regression analysis.

CONCLUSIONS — Our results show that a large percentage of children and adolescents with the metabolic syndrome have elevated concentrations of CRP. Whether the elevated concentrations of CRP among children and adolescents who have the metabolic syndrome predict future adverse health events remains to be determined.

Diabetes Care 28:878–881, 2005

The metabolic syndrome has generated a great deal of interest in recent years. Comprised of a constellation of anthropometric, physiologic, and biochemical abnormalities, the metabolic syndrome is a risk factor for cardiovascular disease and diabetes among adults. However, research about the metabolic syndrome among children and adoles-

cents and the implications of having the metabolic syndrome is limited.

Among adults, components of the metabolic syndrome and the metabolic syndrome itself are associated with measures of inflammation, such as concentrations of C-reactive protein (CRP) (1–4). This low-grade inflammation, which has been associated with an increased risk for

cardiovascular disease and diabetes (5,6), may provide a mechanism for the increased risk of these conditions experienced by individuals who have the metabolic syndrome.

Little is known about whether children and adolescents who have the metabolic syndrome have evidence of inflammation. Because the roots of many adult diseases herald back to childhood, establishing whether young people who have the metabolic syndrome also show evidence of increased inflammation may help to identify children and adolescents who are at high risk for developing cardiovascular disease and diabetes and allow for early prevention of possible adverse health events.

RESEARCH DESIGN AND METHODS

We performed a cross-sectional analysis using data from National Health and Nutrition Examination Survey (NHANES) 1999–2000. Detailed information about the methods and procedures of this survey is available elsewhere (7). In brief, a representative sample of the noninstitutionalized civilian U.S. population was selected through a stratified multistage design. Trained interviewers, using a computer-assisted personal interview system, interviewed participants at home. Participants were asked to attend the mobile examination center where they completed additional questionnaires, underwent various examinations, and provided a blood sample. The study received human subject approval from the Centers for Disease Control and Prevention, Atlanta, Georgia.

To define the metabolic syndrome among the young participants, we used a previously proposed modification of the definition proposed in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP/ATP III) (8). Participants had to meet three of the following five criteria: concentration of triglycerides ≥ 110 mg/dl, HDL cholesterol ≤ 40 mg/dl, waist circumference ≥ 90 th

From the Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.

Address correspondence and reprint requests to Earl Ford, MD, MPH, Centers for Disease Control and Prevention, 4770 Buford Hwy., MS K66, Atlanta, GA 30341. E-mail: eford@cdc.gov.

Received for publication 17 August 2004 and accepted in revised form 19 December 2004.

Abbreviations: CRP, C-reactive protein; NHANES, National Health and Nutrition Examination Survey. A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2005 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Table 1—Unadjusted mean concentrations \pm SE, geometric mean concentrations \pm SE, and percentage \pm SE of CRP >3.0 mg/l by presence or absence of metabolic syndrome or its five components among 1,366 participants aged 12–17 years, National Health and Nutrition Examination Survey 1999–2000

Metabolic syndrome or components	Sample size		Mean \pm SE (mg/l)			Geometric mean \pm SE (mg/l)			% \pm SE of CRP >3 mg/l		
	Yes	No	Yes	No	P	Yes	No	P*	Yes	No	P
Metabolic syndrome (original NCEP/ATP III)	80	1,286	3.8 \pm 1.1	1.4 \pm 0.1	0.038	1.8 \pm 0.4	0.4 \pm 0.03	<0.001	38.4 \pm 10.0	10.3 \pm 1.0	0.007
Metabolic syndrome (modified NCEP/ATP III)	85	1,281	3.9 \pm 1.1	1.4 \pm 0.1	0.030	1.8 \pm 0.4	0.4 \pm 0.03	<0.001	38.1 \pm 9.8	10.3 \pm 1.0	0.007
Abdominal obesity	292	1,074	3.6 \pm 0.4	1.1 \pm 0.2	<0.001	1.9 \pm 0.2	0.4 \pm 0.02	<0.001	36.0 \pm 4.0	6.5 \pm 0.9	<0.001
Hypertriglyceridemia	254	1,112	1.8 \pm 0.3	1.5 \pm 0.2	0.436	0.7 \pm 0.1	0.4 \pm 0.03	0.014	14.4 \pm 3.4	11.1 \pm 1.2	0.370
Low HDL cholesterol	230	1,136	2.1 \pm 0.4	1.4 \pm 0.2	0.132	0.7 \pm 0.1	0.4 \pm 0.03	0.002	16.1 \pm 4.0	10.8 \pm 1.0	0.207
High blood pressure	135	1,231	3.0 \pm 0.9	1.4 \pm 0.1	0.099	0.9 \pm 0.2	0.5 \pm 0.03	0.019	22.5 \pm 5.9	10.9 \pm 1.0	0.053
Hyperglycemia ≥ 110 mg/dl	12	1,354	1.3†	1.6 \pm 0.2	—	0.7†	0.5 \pm 0.03	—	27.6†	11.6 \pm 1.1	—
Hyperglycemia ≥ 100 mg/dl	44	1,322	2.4†	1.5 \pm 0.1	—	0.6†	0.5 \pm 0.03	—	18.4†	11.6 \pm 1.1	—

*P value calculated based on log-transformed concentration of CRP. †Unstable estimates.

percentile (sex specific), glucose concentration ≥ 110 mg/dl, and systolic or diastolic blood pressure ≥ 90 th percentile (age, height, and sex specific). Because a lower threshold of hyperglycemia at ≥ 100 mg/dl has been previously proposed by Grundy et al. (9), we also included this revised definition of hyperglycemia in our analyses and created a modified definition of the metabolic syndrome using the revised definition of hyperglycemia while keeping the other criteria unchanged. For young participants in NHANES 1999–2000, information to define this syndrome was available only for those aged 12–17 years who attended the mobile examination center. To remain consistent with a previous analysis of the metabolic syndrome among adolescents from NHANES III (8), we used a fasting time of ≥ 6 h.

Waist circumference was measured at the high point of the iliac crest at minimal respiration to the nearest 0.1 cm at the end of normal expiration with a steel measuring tape. Up to four blood pressure measurements were obtained for each participant in the mobile examination center. Participants were seated with their right arm (if usable) resting at the level of the heart. Blood pressure was measured with a mercury-gravity manometer. Child, adult, and large arm-cuff sizes were available. Lipid measurements were done at the Johns Hopkins University Lipoprotein Analytical Laboratory. HDL cholesterol concentration, after the precipitation of other lipoproteins with a he-

parin-manganese chloride mixture, was measured on a Hitachi 717 Analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN). To maximize the number of young participants available for analysis, we used measurements of glucose and triglycerides from the biochemistry panel, since the reference measurements for these two variables were only conducted for participants of the morning examination. Glucose concentration was measured using the glucose hexokinase method. Finally, triglyceride concentration was determined after hydrolysis of triglycerides to glycerol and oxidation to dihydroxyacetone phosphate and hydrogen peroxide.

CRP was measured by latex-enhanced nephelometry (N high-sensitivity CRP assay) on a BN II nephelometer (Dade Behring, Deerfield, IL) at the University of Washington Medical Center, Seattle, Washington. Two levels of control materials from Bio-Rad Laboratories (Hercules, CA) were used for quality control purposes, and day-to-day coefficients of variation (CVs) ranged from 4.93 to 7.84%.

T tests were performed to compare mean and log-transformed concentrations of CRP. We examined the independent contribution of the five components of the metabolic syndrome to CRP concentration in multiple linear regression analyses. For regression analyses, CRP concentration was log transformed to improve the distribution of this variable. In addition, we dichotomized concentrations of CRP into ≤ 3.0 and >3.0 mg/l

and used logistic regression analysis to examine the independent contribution of the five components to having a concentration of CRP >3.0 mg/l. To account for the complex sampling design, SUDAAN version 8.0 was used to calculate means and proportions and to perform linear regression analyses (10). Sampling weights were used to calculate proportions, measures of central tendency, and regression estimates. If the relative SE for means or percentages exceeded 30%, the estimates were deemed to be unstable.

RESULTS— A total of 1,782 participants aged 12–17 years attended the mobile examination center. Complete information for the five variables needed to assess the metabolic syndrome was available for 1,554 children and adolescents. The sample size fell to 1,370 after excluding participants who had fasted <6 h and those who were pregnant. After excluding an additional four participants who did not have a value for concentration of CRP, 1,366 participants remained in the analytic sample. Among the 1,366 participants, CRP concentrations ranged from 0.1 to 65.2 mg/l (geometric mean 0.5 mg/l, median 0.4 mg/l).

Among all 1,366 participants, 57.6% had no components, 26.0% had one component, 11.1% had two components, 4.1% had three components, and 1.2% had four components. No participants had all five components. The prevalence of the metabolic syndrome was 5.2% (6.3% among males and 4.1% among females, $P = 0.233$). Furthermore, 17.9%

Table 2—Results of multiple linear regression analysis with concentration of log-transformed CRP as the dependent variable among 1,366 participants aged 12–17 years, National Health and Nutrition Examination Survey 1999–2000

Independent variables	Regression coefficient	SE	P
Age (years)	0.103	0.031	0.002
Sex			
Male vs. female (ref.)	−0.077	0.123	0.534
Abdominal obesity			
Yes vs. no (ref.)	1.677	0.125	<0.001
Hypertriglyceridemia			
Yes vs. no (ref.)	−0.051	0.141	0.720
HDL cholesterol <40 mg/dl			
Yes vs. no (ref.)	0.163	0.130	0.215
High blood pressure			
Yes vs. no (ref.)	0.255	0.171	0.142
Glucose \geq 110 mg/dl			
Yes vs. no (ref.)	0.040	0.261	0.878

had a large waist circumference, 21.0% had hypertriglyceridemia, 18.3% had a low concentration of HDL cholesterol, 7.1% had high blood pressure, 0.8% had a concentration of glucose \geq 110 mg/dl, and 2.7% had a concentration of glucose \geq 100 mg/dl.

Mean and geometric mean concentrations of CRP were higher among participants who had the metabolic syndrome (mean 3.8 mg/l, geometric mean 1.8 mg/l) than among those who did not (mean 1.4 mg/l, geometric mean 0.4 mg/l) (Table 1). Among adolescents with the metabolic syndrome, 38.4% had a concentration of CRP $>$ 3.0 mg/l, a concentration considered to place adults at high risk for cardiovascular disease. In comparison, 10.3% of adolescents without the syndrome had such a concentration of CRP ($P = 0.007$).

Of the five components of the metabolic syndrome, mean concentration of CRP was higher only among those with abdominal obesity (Table 1). However, mean concentrations of log-transformed CRP were higher among participants with abdominal obesity, hypertriglyceridemia, low HDL cholesterol, and high blood pressure compared with participants without those conditions. In multiple logistic regression analysis with age, sex, and all five components of the metabolic syndrome added as independent variables, only abdominal obesity was significantly and independently associated with log-transformed concentration of CRP (Table 2). When the same five com-

ponents were examined as continuous variables in another linear regression model, only waist circumference was significantly associated with concentrations of log-transformed CRP. Results from an analogous logistic regression model with dichotomized concentration of CRP as the dependent variable and the five components added as continuous independent variables yielded similar conclusions.

CONCLUSIONS— Studies have previously demonstrated that adults with the metabolic syndrome show evidence of low-grade inflammation. We have now shown that children and adolescents with the metabolic syndrome are more likely than those without this syndrome to show evidence of low-grade inflammation. The percentage of children and adolescents with an elevated concentration of CRP ($>$ 3.0 mg/l) was almost four times higher among those with the metabolic syndrome compared with those who did not have the syndrome. However, abdominal obesity was the component that was responsible for much of the difference in concentrations of CRP.

The association between obesity and elevated concentrations of CRP in children and adolescents has been clearly established (11–21). In univariate analysis, concentrations of CRP have also been significantly associated with the other four components of the metabolic syndrome (11,13,16–18). However, after adjustment for an anthropometric measure,

many of these associations were seriously weakened and often failed to achieve statistical significance.

No studies have thus far shown that children and adolescents with evidence of low-grade inflammation are more likely to develop cardiovascular disease or diabetes than those without such evidence. However, obesity in childhood does increase the risk for diabetes in childhood and a variety of diseases in adulthood (22).

To maximize our sample size, we decided to use nonreference measurements of concentrations of glucose and triglycerides because these were obtained for children who attended any of the three examination sessions. However, when we used reference measurements for the young participants who attended the morning examination, we obtained very similar results. Unfortunately, the sample size was inadequate to provide results separately for males and females.

Our results suggest that the presence of the metabolic syndrome and abdominal obesity among children and adolescents may be laying the foundation for the emergence of cardiovascular disease and diabetes later in life through early low-grade inflammation. To reduce the potential adverse effects of the inflammation that accompanies the metabolic syndrome, children and adolescents with this syndrome should avoid excessive energy intake, limit sedentary behavior, and increase their participation in activities that increase their energy expenditure.

References

1. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). *Circulation* 102:42–47, 2000
2. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. *Diabetes Care* 23:1835–1839, 2000
3. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. *Circulation* 107:391–397, 2003
4. Ford ES: The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third

- National Health and Nutrition Examination Survey. *Atherosclerosis* 168:351–358, 2003
5. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med* 350:1387–1397, 2004
 6. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* 286:327–334, 2001
 7. Centers for Disease Control and Prevention: NHANES 1999–2000 public data release file documentation [article online]. Hyattsville, MD, National Center for Health Statistics. Accessed 15 January 2003. Available from <http://www.cdc.gov/nchs/about/major/nhanes/currentnhanes.htm>
 8. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH: Prevalence of a metabolic syndrome phenotype in adolescents: findings from the Third National Health and Nutrition Examination Survey, 1988–1994. *Arch Pediatr Adolesc Med* 157:821–827, 2003
 9. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart Association, National Heart, Lung, and Blood Institute: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 109:433–438, 2004
 10. SUDAAN User's Manual. Release 8.0. Research Triangle Park, NC, Research Triangle Institute, 2001
 11. Cook DG, Mendall MA, Whincup PH, Carey IM, Ballam L, Morris JE, Miller GJ, Strachan DP: C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. *Atherosclerosis* 149:139–150, 2000
 12. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: Low-grade systemic inflammation in overweight children. *Pediatrics* 107:E13, 2001
 13. Ford ES, Galuska DA, Gillespie C, Will JC, Giles WH, Dietz WH: C-reactive protein and body mass index in children: findings from the Third National Health and Nutrition Examination Survey, 1988–1994. *J Pediatr* 138:486–492, 2001
 14. Barbeau P, Litaker MS, Woods KF, Lemon CR, Humphries MC, Owens S, Gutin B: Hemostatic and inflammatory markers in obese youths: effects of exercise and adiposity. *J Pediatr* 141:415–420, 2002
 15. Shea S, Aymong E, Zybert P, Shamooh H, Tracy RP, Deckelbaum RJ, Basch CE: Obesity, fasting plasma insulin, and C-reactive protein levels in healthy children. *Obes Res* 11:95–103, 2003
 16. Wu DM, Chu NF, Shen MH, Chang JB: Plasma C-reactive protein levels and their relationship to anthropometric and lipid characteristics among children. *J Clin Epidemiol* 56:94–100, 2003
 17. Vikram NK, Misra A, Dwivedi M, Sharma R, Pandey RM, Luthra K, Chatterjee A, Dhingra V, Jaiikhani BL, Talwar KK, Guleria R: Correlations of C-reactive protein levels with anthropometric profile, percentage of body fat and lipids in healthy adolescents and young adults in urban North India. *Atherosclerosis* 168:305–313, 2003
 18. Hiura M, Kikuchi T, Nagasaki K, Uchiyama M: Elevation of serum C-reactive protein levels is associated with obesity in boys. *Hypertens Res* 26:541–546, 2003
 19. Ford ES: C-reactive protein concentration and cardiovascular disease risk factors in children: findings from the National Health and Nutrition Examination Survey 1999–2000. *Circulation* 108:1053–1058, 2003
 20. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S: Obesity and the metabolic syndrome in children and adolescents. *N Engl J Med* 350:2362–2374, 2004
 21. Lambert M, Delvin EE, Paradis G, O'Loughlin J, Hanley JA, Levy E: C-reactive protein and features of the metabolic syndrome in a population-based sample of children and adolescents. *Clin Chem* 50:1762–1768, 2004
 22. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH: Long-term morbidity and mortality of overweight adolescents: a follow-up of the Harvard Growth Study of 1922 to 1935. *N Engl J Med* 327:1350–1355, 1992